Self-Assembled Nanoparticles from Phenolic Derivatives for Cancer Therapy
Self-Assembled Nanoparticles from Phenolic Derivatives for Cancer Therapy
复制标题
DOI：
10.1002/adhm.201700467
复制
发表时间：
2017-08-23
影响因子：
10
通讯作者：
Caruso, Frank
中科院分区：
文献类型：
--
作者：
Dai, Yunlu;Guo, Junling;Caruso, Frank
治疗性纳米颗粒通过避免常规药物的限制而具有癌症治疗的临床前景。在此，介绍了一种简便快速的方法来组装聚（乙二醇）（PEG）-改性的Pt前药纳米复合物，通过金属-多酚络合和乳化相结合，这导致约100 nm直径的纳米粒子（PtP NP），表现出高载药量（0.15 fg Pt/纳米粒子）和低污染性能。PtP NP被表征为作为癌症治疗剂的潜在用途。使用质谱细胞术来定量体外单个细胞中纳米颗粒的摄取和药物浓度。PtP NP具有较长的循环时间，在健康小鼠中的消除半衰期约为18小时。在人前列腺癌异种移植小鼠模型中系统地研究PtP NPs的体内抗肿瘤活性。用PtP NP处理的小鼠显示出比游离前药或顺铂更好的四倍的肿瘤生长抑制。这项研究提出了一个很有前途的战略，以制备治疗纳米粒子的生物医学应用。
Therapeutic nanoparticles hold clinical promise for cancer treatment by avoiding limitations of conventional pharmaceuticals. Herein, a facile and rapid method is introduced to assemble poly(ethylene glycol) (PEG)-modified Pt prodrug nanocomplexes through metal-polyphenol complexation and combined with emulsification, which results in approximate to 100 nm diameter nanoparticles (PtP NPs) that exhibit high drug loading (0.15 fg Pt per nanoparticle) and low fouling properties. The PtP NPs are characterized for potential use as cancer therapeutics. Mass cytometry is used to quantify uptake of the nanoparticles and the drug concentration in individual cells in vitro. The PtP NPs have long circulation times, with an elimination half-life of approximate to 18 h in healthy mice. The in vivo antitumor activity of the PtP NPs is systematically investigated in a human prostate cancer xenograft mouse model. Mice treated with the PtP NPs demonstrate four times better inhibition of tumor growth than either free prodrug or cisplatin. This study presents a promising strategy to prepare therapeutic nanoparticles for biomedical applications.